Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
Axsome Therapeutics (NASDAQ: AXSM) is hosting its Frontiers in Brain Health R&D Day to showcase its extensive CNS pipeline. The event features presentations from six leading expert clinicians who will discuss various neurological and psychiatric conditions including Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation.
Key speakers include renowned experts who will present clinical data and trial results for various drug candidates including AXS-14 for fibromyalgia, AXS-05 for Alzheimer's disease agitation, solriamfetol for ADHD and MDD, SYMBRAVO for migraine, and AXS-12 for narcolepsy. The event will be accessible via webcast for institutional investors and sell-side analysts.
Axsome Therapeutics (NASDAQ: AXSM) organizza il suo Frontiers in Brain Health R&D Day per presentare il suo ampio portafoglio di ricerca nel campo del sistema nervoso centrale. L'evento prevede interventi di sei esperti clinici di primo piano che discuteranno diverse patologie neurologiche e psichiatriche, tra cui agitazione nella malattia di Alzheimer, depressione, narcolessia, fibromialgia, ADHD e cessazione del fumo.
I relatori principali sono esperti riconosciuti che presenteranno dati clinici e risultati di studi su vari candidati farmaci, tra cui AXS-14 per la fibromialgia, AXS-05 per l'agitazione nella malattia di Alzheimer, solriamfetol per ADHD e depressione maggiore, SYMBRAVO per l'emicrania e AXS-12 per la narcolessia. L'evento sarà fruibile in webcast per investitori istituzionali e analisti sell-side.
Axsome Therapeutics (NASDAQ: AXSM) organiza su Frontiers in Brain Health R&D Day para mostrar su amplia cartera en el área del sistema nervioso central. El evento contará con presentaciones de seis destacados expertos clínicos que abordarán diversas condiciones neurológicas y psiquiátricas, incluyendo agitación en la enfermedad de Alzheimer, depresión, narcolepsia, fibromialgia, TDAH y cesación del tabaquismo.
Los ponentes principales son expertos reconocidos que presentarán datos clínicos y resultados de ensayos de varios candidatos a fármaco, incluyendo AXS-14 para fibromialgia, AXS-05 para agitación en Alzheimer, solriamfetol para TDAH y trastorno depresivo mayor, SYMBRAVO para migraña y AXS-12 para narcolepsia. El evento estará disponible vía webcast para inversores institucionales y analistas sell-side.
Axsome Therapeutics (NASDAQ: AXSM)는 광범위한 중추신경계(CNS) 파이프라인을 선보이기 위해 Frontiers in Brain Health R&D Day를 개최합니다. 이번 행사에는 여섯 명의 저명한 임상 전문가가 참여하여 알츠하이머병 불안, 우울증, 기면증, 섬유근육통, ADHD, 금연 등 다양한 신경학적 및 정신과적 질환에 대해 논의할 예정입니다.
주요 연사들은 섬유근육통 치료제 AXS-14, 알츠하이머병 불안 치료제 AXS-05, ADHD 및 주요 우울장애 치료제 솔리아마페톨, 편두통 치료제 SYMBRAVO, 기면증 치료제 AXS-12 등 여러 후보 약물의 임상 데이터와 시험 결과를 발표할 예정입니다. 이번 행사는 기관 투자자 및 셀사이드 애널리스트를 위해 웹캐스트로도 제공됩니다.
Axsome Therapeutics (NASDAQ : AXSM) organise son Frontiers in Brain Health R&D Day afin de présenter son vaste portefeuille de recherche sur le système nerveux central. L'événement comprend des présentations de six experts cliniciens de renom qui aborderont diverses pathologies neurologiques et psychiatriques, notamment l'agitation liée à la maladie d'Alzheimer, la dépression, la narcolepsie, la fibromyalgie, le TDAH et l'arrêt du tabac.
Les intervenants clés sont des experts reconnus qui présenteront des données cliniques et les résultats d'essais pour plusieurs candidats médicaments, notamment AXS-14 pour la fibromyalgie, AXS-05 pour l'agitation liée à Alzheimer, le solriamfétol pour le TDAH et le trouble dépressif majeur, SYMBRAVO pour la migraine, et AXS-12 pour la narcolepsie. L'événement sera accessible en webcast pour les investisseurs institutionnels et les analystes sell-side.
Axsome Therapeutics (NASDAQ: AXSM) veranstaltet seinen Frontiers in Brain Health R&D Day, um seine umfangreiche Pipeline im Bereich des zentralen Nervensystems vorzustellen. Die Veranstaltung umfasst Präsentationen von sechs führenden klinischen Experten, die verschiedene neurologische und psychiatrische Erkrankungen wie Agitation bei Alzheimer, Depression, Narkolepsie, Fibromyalgie, ADHS und Rauchentwöhnung diskutieren werden.
Zu den Hauptrednern zählen renommierte Experten, die klinische Daten und Studienergebnisse zu verschiedenen Medikamentenkandidaten vorstellen, darunter AXS-14 für Fibromyalgie, AXS-05 für Agitation bei Alzheimer, Solriamfetol für ADHS und Major Depression, SYMBRAVO für Migräne und AXS-12 für Narkolepsie. Die Veranstaltung wird für institutionelle Investoren und Sell-Side-Analysten per Webcast zugänglich sein.
- None.
- None.
Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses
Presentations by expert clinicians and key opinion leaders
Company to webcast its R&D Day event today at 11:00 AM Eastern
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host its Frontiers in Brain Health R&D Day today in New York City to review its industry-leading CNS pipeline.
The Frontiers in Brain Health R&D Day will feature presentations from the following six leading expert clinicians and key opinion leaders, who will discuss the psychiatric and neurological conditions targeted by the company’s pipeline, and present clinical data from the pipeline programs:
- Andrea Chadwick, MD, MSc, FASA, Kasumi Arakawa Professor of Anesthesiology, Pain, and Perioperative Medicine and Director of the Fibromyalgia and Centralized Pain Exploration (FACE) Lab; University of Kansas Medical Center. Dr. Chadwick will provide an overview of fibromyalgia and of the previously completed Phase 2 and Phase 3 clinical trials of AXS-14 in the indication.
- Jeffrey Cummings, MD, ScD, Joy Chambers-Grundy Professor of Brain Science, Chair of the Chambers-Grundy Center for Transformative Neuroscience, and Clinical Professor Neurology, UNLV Department of Brain Health. Dr. Cummings will provide an overview of Alzheimer's disease (AD) agitation and discuss the results of the ADVANCE and ACCORD Phase 3 trials of AXS-05 in the indication.
- Andrew Cutler, MD, Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University. Dr Cutler will provide an overview of attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD) with excessive daytime sleepiness (EDS), and excessive sleepiness associated with shift work disorder (SWD), and discuss the results of the FOCUS and PARADIGM Phase 3 trials of solriamfetol in ADHD and MDD, respectively.
- Susan McElroy, MD, Professor of Psychiatry & Behavioral Neuroscience and Chief Research Officer and Director of Psychopharmacology Research at the Lindner Center of HOPE, University of Cincinnati. Dr. McElroy will provide an overview of binge eating disorder (BED).
- Stewart J. Tepper, MD, Vice President at The New England Institute for Neurology and Headache and Professor Neurology, Geisel School of Medicine at Dartmouth. Dr. Tepper will provide an overview of migraine and will discuss results from the MOMENTUM and INTERCEPT Phase 3 trials of SYMBRAVO® in the acute treatment of migraine with and without aura.
- Michael Thorpy, MD, Professor of Neurology and Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center, Albert Einstein College of Medicine. Dr. Thorpy will provide an overview of narcolepsy and will discuss the results of the clinical trial program of AXS-12 in the indication.
The presenters and the management team will be available to answer questions at the end of the presentations. To access the event, please click here.
Webcast Information
This event is intended for institutional investors and sell-side analysts. To register for the live webcast, please click here. The live webcast and a replay of the event will also be publicly available on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at www.axsome.com.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
mjacobson@axsome.com
Media:
Darren Opland
Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
FAQ
When is Axsome Therapeutics (AXSM) hosting its R&D Day event?
What drug candidates will be discussed at Axsome's R&D Day?
Who are the key speakers at Axsome's R&D Day?
How can investors access Axsome's R&D Day presentation?
